Market Research Reports and Industry Reports

Kymab Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
Summary

Kymab Ltd (Kymab) is a biopharmaceutical company that discovers and develops fully human monoclonal antibody drugs. The company offers pipepline of assets in three therapeutic areas such as immuno-oncology, immunology and opportunistic. Its products pipeline includes KY1003-Anti PD-L1, KY1006-Anti-LIGHT, KY1005-Anti-OX40L, KV7005, KY1041, KY1040, KY1036, KY1034, KY1020, KY1017, KY1016, KY1015 and KY1007. Kymab utilizes its proprietary Kymouse antibody, transgenic mouse platform to generate human antibodies against disease targets. The companys pipeline treats various diseases including immunology, chronic anemia, chronic pain, dyslipidemia, infectious diseases, immune-oncology, ebola, and orphan oncology, among others. It also offers pre-clinical and clinical development services. The company collaborates with pharmaceutical, biotechnology and academic partners to discover, develop and commercialise monoclonal antibodies in various therapeutic areas. Kymab is headquartered in Cambridge, the UK.

Kymab Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Kymab Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Kymab Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Kymab Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Kymab Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Kymab Raises USD100.5 Million in Series C Financing 11
Kymab Raises Additional USD50 Million in Series B Financing 13
Kymab Raises USD40 Million in Series B Financing 14
Partnerships 15
Heptares Therapeutics to Form Partnership with Kymab 15
Kymab Enters into Agreement with University of Texas MD Anderson 16
Kymab Enters into Partnership Agreement with Dr Stephen Gillies 17
Licensing Agreements 18
EpimAb Biotherapeutics Enters into Licensing Agreement with Kymab 18
Novo Nordisk Enters Into Licensing Agreement With Kymab For Kymouse 19
Kymab Ltd - Key Competitors 20
Kymab Ltd - Key Employees 21
Kymab Ltd - Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Corporate Communications 23
May 09, 2017: Kymab Group appoints chief medical officer 23
May 09, 2017: Sonia Quaratino appointed Kymab CMO 24
Jan 23, 2017: Kymab appoints Dr Arndt Schottelius as Executive Vice President Research & Development 25
Mar 17, 2016: Kymab appoints Dr David Chi swell as Chief Executive Officer 26
Legal and Regulatory 27
Feb 02, 2016: Kymab Succeeds in Revoking Regenerons UK VelocImmune Patents 27
Government and Public Interest 28
Jan 09, 2017: Kymab expands Infectious Disease Programmes 28
Product News 29
Sep 09, 2016: Kymouse, Kymabs Human Antibody Discovery Platform, Successfully Demonstrates Steps to Developing HIV Vaccine 29
03/24/2016: New findings in humans provide encouraging foundation for upcoming AIDS vaccine clinical trial 31
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List Of Tables


Kymab Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Kymab Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Kymab Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Kymab Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Kymab Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Kymab Raises USD100.5 Million in Series C Financing 11
Kymab Raises Additional USD50 Million in Series B Financing 13
Kymab Raises USD40 Million in Series B Financing 14
Heptares Therapeutics to Form Partnership with Kymab 15
Kymab Enters into Agreement with University of Texas MD Anderson 16
Kymab Enters into Partnership Agreement with Dr Stephen Gillies 17
EpimAb Biotherapeutics Enters into Licensing Agreement with Kymab 18
Novo Nordisk Enters Into Licensing Agreement With Kymab For Kymouse 19
Kymab Ltd, Key Competitors 20
Kymab Ltd, Key Employees 21

List Of Figures


Kymab Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Kymab Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Kymab Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Kymab Ltd, Medical Devices Deals, 2011 to YTD 2017 9

Kymab Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Kymab Ltd (Kymab) is a biopharmaceutical company that discovers and develops fully human monoclonal antibody drugs. The company offers pipepline of assets in three therapeutic areas such as immuno-oncology, immunology

USD 250View Report

Kymab Ltd - Product Pipeline Review - 2016

Kymab Ltd - Product Pipeline Review - 2016Global Markets Directs, Kymab Ltd - Product Pipeline Review - 2016, provides an overview of the Kymab Ltds pharmaceutical research and development focus.

USD 1500View Report

SBI Pharmaceuticals Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

SBI Pharmaceuticals Co Ltd (SBI Pharma), formerly SBI Alapromo Co., Ltd., is a healthcare solution provider that develops and manufactures 5-ALA (5-Aminolevulinic Acid) based products in the areas of medicines

USD 250View Report

SR One Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

SR One Ltd. (SR One), a subsidiary of GlaxoSmithKline Plc is a financial services company that offers investment services. The company invests globally in emerging life science companies that are

USD 250View Report

Sinovac Biotech Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Sinovac Biotech Ltd (Sinovac Biotech) is a biopharmaceutical company that develops, manufactures and commercializes vaccines to eliminate human diseases. The companys products include healive, bilive, anflu, panflu and panflu, among

USD 250View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
Country Code.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Aug 2017
No. of Pages :33
Country :United Kingdom
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube
paykasa bozdurma,paykasa bozdurma,astropay bozdurma,paykasa,paykasa,paykasa bozdurma,paykasa,astropay bozdurma,justin kart,bitcoin bozdurma,paykasa bozum,paykasa kart bozdurma,
beylikduzu escort,bahçeşehir escort,escort istanbul,istanbul escort,sex hikayeleri,pendik escort,
pedalebiellese.com,
istanbul escort bayan,besiktas escort,maltepe escort,kadikoy escort bayan,tekirdag escort bayan,findikzade escort,antalya escort bayan,ankara escort bayan,
Böcek İlaçlama,şehirler arası nakliyat,şehirler arası evden eve nakliyat,ofis taşıma,gebze evden eve nakliyat,kadıköy evden eve nakliyat,istanbul evden eve nakliyat,epoksi zemin,
ankara escort,ankara escort,ankara escort,
tipobet,
seo teknikleri wordpress ücretsiz tema istanbul sexs shop hacklink e sigara sexs shop